US5560922A
(en)
*
|
1986-05-30 |
1996-10-01 |
Rutgers, The State University Of New Jersey |
Transdermal absorption dosage unit using a polyacrylate adhesive polymer and process
|
US5229129A
(en)
*
|
1989-07-12 |
1993-07-20 |
Cygnus Therapeutic Systems |
Transdermal administration of lisuride
|
NZ237241A
(en)
*
|
1990-03-02 |
1993-11-25 |
Pharmetrix Corp |
Method for increasing the storage stability of physostigmine
|
EP0523150A4
(en)
*
|
1990-04-06 |
1993-09-29 |
Pharmetrix Corporation |
Device and method for enhanced administration of physostigmine
|
US5225198A
(en)
*
|
1991-08-27 |
1993-07-06 |
Cygnus Therapeutic Systems |
Transdermal administration of short or intermediate half-life benzodiazepines
|
US5518734A
(en)
*
|
1991-09-25 |
1996-05-21 |
Beta Pharmaceuticals Co. |
Transdermal delivery system for estradiol and process for manufacturing said device
|
US5705185A
(en)
*
|
1991-09-25 |
1998-01-06 |
Beta Pharmaceuticals Co. |
Transdermal delivery of estradiol and process for manufacturing said device
|
US5229130A
(en)
*
|
1991-12-20 |
1993-07-20 |
Cygnus Therapeutics Systems |
Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems
|
US5453279A
(en)
*
|
1992-04-21 |
1995-09-26 |
Tbs Laboratories, Inc. |
Enhancing transdermal absorption compositions; transdermal dosage form; and process
|
US6746691B2
(en)
|
1993-09-20 |
2004-06-08 |
Kos Pharmaceuticals, Inc. |
Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
|
US6080428A
(en)
|
1993-09-20 |
2000-06-27 |
Bova; David J. |
Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
|
US6818229B1
(en)
|
1993-09-20 |
2004-11-16 |
Kos Pharmaceuticals, Inc. |
Intermediate release nicotinic acid compositions for treating hyperlipidemia
|
US6676967B1
(en)
|
1993-09-20 |
2004-01-13 |
Kos Pharmaceuticals, Inc. |
Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
|
JPH0827003A
(ja)
*
|
1994-07-22 |
1996-01-30 |
Sekisui Chem Co Ltd |
経皮吸収製剤
|
EP0781122B1
(de)
*
|
1994-09-14 |
2000-07-05 |
Minnesota Mining And Manufacturing Company |
Matrix für transdermale wirkstofffreisetzung
|
GB9500116D0
(en)
*
|
1995-01-05 |
1995-03-01 |
Ciba Geigy Ag |
Pharmaceutical compositions
|
US5573778A
(en)
*
|
1995-03-17 |
1996-11-12 |
Adhesives Research, Inc. |
Drug flux enhancer-tolerant pressure sensitive adhesive composition
|
US5882676A
(en)
*
|
1995-05-26 |
1999-03-16 |
Alza Corporation |
Skin permeation enhancer compositions using acyl lactylates
|
US6572879B1
(en)
*
|
1995-06-07 |
2003-06-03 |
Alza Corporation |
Formulations for transdermal delivery of pergolide
|
EP1563788B8
(de)
|
1995-08-29 |
2015-04-08 |
Nitto Denko Corporation |
Mikroperforation von menschlicher Haut zur Medikamentenverabreichung und Überwachungsanwendungen
|
DE19548332A1
(de)
*
|
1995-12-22 |
1997-07-10 |
Rotta Res Bv |
Hormonpflaster
|
WO1997034607A1
(en)
*
|
1996-03-20 |
1997-09-25 |
Glaxo Group Limited |
Topical formulations of aciclovir
|
IT1283102B1
(it)
*
|
1996-06-06 |
1998-04-07 |
Permatec Nv |
Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele
|
AU4990797A
(en)
*
|
1996-10-24 |
1998-05-15 |
Alza Corporation |
Permeation enhancers for transdermal drug delivery compositions, devices, and methods
|
JP2001503062A
(ja)
*
|
1996-10-30 |
2001-03-06 |
セラテック・インコーポレーテッド |
透過促進剤としての乳酸の脂肪酸エステルの塩
|
KR100215027B1
(ko)
*
|
1997-01-27 |
1999-08-16 |
성재갑 |
스테로이드계 약물의 경피흡수투여용 조성물 및 이를 포함하는 경피흡수투여용 제형
|
KR100294084B1
(ko)
*
|
1998-06-02 |
2001-09-22 |
성재갑 |
비-스테로이드성소염진통제의경피흡수투여용조성물및이를포함하는경피흡수투여용제형
|
US6572874B1
(en)
*
|
1998-05-15 |
2003-06-03 |
Umd, Inc. |
Vaginal delivery of bisphosphonates
|
IT1294748B1
(it)
|
1997-09-17 |
1999-04-12 |
Permatec Tech Ag |
Formulazione per un dispositivo transdermico
|
US6414028B1
(en)
*
|
1997-11-05 |
2002-07-02 |
Nexmed Holdings, Inc. |
Topical compositions containing prostaglandin E1
|
US6046244A
(en)
*
|
1997-11-05 |
2000-04-04 |
Nexmed Holdings, Inc. |
Topical compositions for prostaglandin E1 delivery
|
AU1728099A
(en)
|
1997-12-22 |
1999-07-12 |
Alza Corporation |
Monoglyceride and ethyl palmitate permeation enhancer compositions
|
DE19814084B4
(de)
*
|
1998-03-30 |
2005-12-22 |
Lts Lohmann Therapie-Systeme Ag |
D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
|
DE69936195T2
(de)
*
|
1998-04-27 |
2007-09-13 |
Astellas Pharma Inc. |
Pharmazeutische gelformulierung enthaltend eine trizyklische substanz (fk-506/tacrolimus)
|
FR2761600B1
(fr)
*
|
1998-06-19 |
2000-03-31 |
Oreal |
Composition moussante pour le lavage et le traitement des cheveux et/ou du cuir chevelu a base d'un principe actif, d'un tensioactif anionique, d'un tensioactif amphotere et d'un agent propenetrant
|
GB9825402D0
(en)
†
|
1998-11-19 |
1999-01-13 |
Pfizer Ltd |
Antiparasitic formulations
|
US20030078499A1
(en)
*
|
1999-08-12 |
2003-04-24 |
Eppstein Jonathan A. |
Microporation of tissue for delivery of bioactive agents
|
USRE44145E1
(en)
|
2000-07-07 |
2013-04-09 |
A.V. Topchiev Institute Of Petrochemical Synthesis |
Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties
|
US8980290B2
(en)
|
2000-08-03 |
2015-03-17 |
Antares Pharma Ipl Ag |
Transdermal compositions for anticholinergic agents
|
US7198801B2
(en)
|
2000-08-03 |
2007-04-03 |
Antares Pharma Ipl Ag |
Formulations for transdermal or transmucosal application
|
WO2002011768A1
(en)
*
|
2000-08-03 |
2002-02-14 |
Antares Pharma Ipl Ag |
Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
|
US20040198706A1
(en)
*
|
2003-03-11 |
2004-10-07 |
Carrara Dario Norberto R. |
Methods and formulations for transdermal or transmucosal application of active agents
|
US20070225379A1
(en)
*
|
2001-08-03 |
2007-09-27 |
Carrara Dario Norberto R |
Transdermal delivery of systemically active central nervous system drugs
|
DE10041478A1
(de)
|
2000-08-24 |
2002-03-14 |
Sanol Arznei Schwarz Gmbh |
Neue pharmazeutische Zusammensetzung
|
US8206738B2
(en)
|
2001-05-01 |
2012-06-26 |
Corium International, Inc. |
Hydrogel compositions with an erodible backing member
|
US6803420B2
(en)
|
2001-05-01 |
2004-10-12 |
Corium International |
Two-phase, water-absorbent bioadhesive composition
|
US8840918B2
(en)
|
2001-05-01 |
2014-09-23 |
A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences |
Hydrogel compositions for tooth whitening
|
US8541021B2
(en)
|
2001-05-01 |
2013-09-24 |
A.V. Topchiev Institute Of Petrochemical Synthesis |
Hydrogel compositions demonstrating phase separation on contact with aqueous media
|
US20050113510A1
(en)
|
2001-05-01 |
2005-05-26 |
Feldstein Mikhail M. |
Method of preparing polymeric adhesive compositions utilizing the mechanism of interaction between the polymer components
|
US20050215727A1
(en)
|
2001-05-01 |
2005-09-29 |
Corium |
Water-absorbent adhesive compositions and associated methods of manufacture and use
|
ATE438418T1
(de)
|
2001-05-01 |
2009-08-15 |
Av Topchiev Inst Petrochemical |
Hydrogel-zusammensetzungen
|
NZ532769A
(en)
*
|
2001-11-29 |
2005-12-23 |
3M Innovative Properties Co |
Pharmaceutical formulations comprising an immune response modifier
|
DE10159120B4
(de)
*
|
2001-12-01 |
2006-08-17 |
Lts Lohmann Therapie-Systeme Ag |
Steroidhormonhaltige transdermale therapeutische Systeme enthaltend Propylenglycolmonocaprylat und seine Verwendung
|
US20040033253A1
(en)
*
|
2002-02-19 |
2004-02-19 |
Ihor Shevchuk |
Acyl opioid antagonists
|
US9918665B2
(en)
|
2002-03-11 |
2018-03-20 |
Nitto Denko Corporation |
Transdermal porator and patch system and method for using same
|
AU2003265226A1
(en)
|
2002-03-11 |
2003-12-19 |
Altea Therapeutics Corporation |
Transdermal drug delivery device, method and use
|
US8116860B2
(en)
*
|
2002-03-11 |
2012-02-14 |
Altea Therapeutics Corporation |
Transdermal porator and patch system and method for using same
|
US20030199584A1
(en)
*
|
2002-04-11 |
2003-10-23 |
Ahluwalia Gurpreet S. |
Reduction of hair growth
|
US8211462B2
(en)
*
|
2002-07-30 |
2012-07-03 |
Ucb Pharma Gmbh |
Hot-melt TTS for administering rotigotine
|
DE10234673B4
(de)
*
|
2002-07-30 |
2007-08-16 |
Schwarz Pharma Ag |
Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
|
US8246980B2
(en)
*
|
2002-07-30 |
2012-08-21 |
Ucb Pharma Gmbh |
Transdermal delivery system
|
US8246979B2
(en)
|
2002-07-30 |
2012-08-21 |
Ucb Pharma Gmbh |
Transdermal delivery system for the administration of rotigotine
|
JP4642467B2
(ja)
*
|
2002-08-20 |
2011-03-02 |
ユーロ−セルティーク エス.エイ. |
活性剤及び塩並びに副作用物質の遊離塩基形を含む経皮剤形
|
EP1556501A4
(de)
|
2002-10-28 |
2009-04-08 |
Transform Pharmaceuticals Inc |
Transdermaler assay mit magnetischerklemme
|
DE60204229T2
(de)
*
|
2002-12-02 |
2006-02-02 |
Schwarz Pharma Ag |
Verabreichung von Rotigotine zur Behandlung der Parkinson'schen Krankheit durch Iontophorese
|
CA2729967C
(en)
*
|
2002-12-13 |
2018-01-16 |
Schering-Plough Healthcare Products, Inc. |
Use of a transdermal or transmucosal ingredient delivery device
|
JP4542743B2
(ja)
*
|
2002-12-26 |
2010-09-15 |
Kdl株式会社 |
ピリドン誘導体の溶液状医薬組成物
|
DE10261696A1
(de)
*
|
2002-12-30 |
2004-07-15 |
Schwarz Pharma Ag |
Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
|
US7858607B2
(en)
*
|
2003-03-14 |
2010-12-28 |
Mamchur Stephen A |
System for use by compounding pharmacists to produce hormone replacement medicine customized for each consumer
|
US20040241223A1
(en)
*
|
2003-05-27 |
2004-12-02 |
David Wong |
Oral dosage forms for macromolecular drugs
|
US7816546B2
(en)
*
|
2003-06-30 |
2010-10-19 |
Richter Gedeon Vegyeszeti Gyar Rt. |
Process for the synthesis of high purity d-(17α)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene-20-yn-3-one-oxime
|
WO2005007020A2
(en)
|
2003-07-03 |
2005-01-27 |
Corium International, Inc. |
Wound dressing, ingredient delivery device and iv hold-down, and method relating to same
|
US20080020028A1
(en)
*
|
2003-08-20 |
2008-01-24 |
Euro-Celtique S.A. |
Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent
|
AU2004283431B2
(en)
*
|
2003-10-10 |
2009-09-10 |
Antares Pharma Ipl Ag |
Transdermal pharmaceutical formulation for minimizing skin residues
|
US8016811B2
(en)
|
2003-10-24 |
2011-09-13 |
Altea Therapeutics Corporation |
Method for transdermal delivery of permeant substances
|
US7105263B2
(en)
*
|
2003-12-30 |
2006-09-12 |
Samsung Electronics Company |
Dry toner comprising encapsulated pigment, methods and uses
|
WO2005074894A1
(en)
|
2004-01-30 |
2005-08-18 |
Corium International |
Rapidly dissolving film for delivery of an active agent
|
WO2005077364A1
(ja)
*
|
2004-02-18 |
2005-08-25 |
Yamanouchi Pharmaceutical Co., Ltd. |
ソリフェナシンの経皮投与製剤およびその経皮透過改善方法
|
US7425340B2
(en)
*
|
2004-05-07 |
2008-09-16 |
Antares Pharma Ipl Ag |
Permeation enhancing compositions for anticholinergic agents
|
US20060008432A1
(en)
*
|
2004-07-07 |
2006-01-12 |
Sebastiano Scarampi |
Gilsonite derived pharmaceutical delivery compositions and methods: nail applications
|
EP1786331A2
(de)
*
|
2004-07-15 |
2007-05-23 |
Freedom-2, LLC |
Modifiziertes gewebemarkierungspigment und modifizierungsverfahren für gewebemarkierungspigment
|
CN103497713B
(zh)
|
2004-08-05 |
2018-07-17 |
考里安国际公司 |
粘合剂组合物
|
EP2338881A1
(de)
|
2005-02-23 |
2011-06-29 |
Prexa Pharmaceuticals, Inc. |
Inhibitoren des Dopamintransporters zur Verwendung bei der Behandlung von Bewegungserkrankungen und anderen ZNS-Indikationen
|
WO2007124250A2
(en)
|
2006-04-21 |
2007-11-01 |
Antares Pharma Ipl Ag |
Methods of treating hot flashes with formulations for transdermal or transmucosal application
|
WO2006125642A1
(en)
|
2005-05-27 |
2006-11-30 |
Antares Pharma Ipl Ag |
Methods and apparatus for transdermal or transmucosal application of testosterone
|
US20070065494A1
(en)
*
|
2005-08-03 |
2007-03-22 |
Watson Laboratories, Inc. |
Formulations and Methods for Enhancing the Transdermal Penetration of a Drug
|
US10137135B2
(en)
*
|
2005-08-15 |
2018-11-27 |
Allergan Sales, Llc |
Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith
|
DE102006050558B4
(de)
*
|
2006-10-26 |
2009-03-26 |
Lts Lohmann Therapie-Systeme Ag |
Transdermales therapeutisches System enthaltend Norelgestromin zur Kontrazeption und Hormonsubstitution
|
US20100278935A1
(en)
*
|
2007-07-30 |
2010-11-04 |
Stacey William C |
Immune System Modulator Formulation
|
US20090098191A1
(en)
*
|
2007-10-16 |
2009-04-16 |
Anderson Christopher G |
Use of bases to stabilize transdermal formulations
|
US8609733B2
(en)
*
|
2008-05-19 |
2013-12-17 |
Massachusetts Institute Of Technology |
Sensory-specific local anesthesia and prolonged duration local anesthesia
|
US8658699B2
(en)
*
|
2008-05-19 |
2014-02-25 |
Massachusetts Institute Of Technology |
Chemical permeation enhancers enhance nerve blockade by toxins
|
AU2010204986B2
(en)
|
2009-01-14 |
2016-06-02 |
Corium International, Inc. |
Transdermal administration of tamsulosin
|
US9041541B2
(en)
|
2010-01-28 |
2015-05-26 |
Seventh Sense Biosystems, Inc. |
Monitoring or feedback systems and methods
|
WO2010101625A2
(en)
|
2009-03-02 |
2010-09-10 |
Seventh Sense Biosystems, Inc. |
Oxygen sensor
|
EP2408372B1
(de)
|
2009-03-02 |
2019-01-09 |
Seventh Sense Biosystems, Inc. |
Vorrichtungen im zusammenhang mit der entnahme von blutproben
|
US20120277629A1
(en)
|
2011-04-29 |
2012-11-01 |
Seventh Sense Biosystems, Inc. |
Systems and methods for collection and/or manipulation of blood spots or other bodily fluids
|
US9295417B2
(en)
|
2011-04-29 |
2016-03-29 |
Seventh Sense Biosystems, Inc. |
Systems and methods for collecting fluid from a subject
|
WO2012018486A2
(en)
|
2010-07-26 |
2012-02-09 |
Seventh Sense Biosystems, Inc. |
Rapid delivery and/or receiving of fluids
|
US9033898B2
(en)
|
2010-06-23 |
2015-05-19 |
Seventh Sense Biosystems, Inc. |
Sampling devices and methods involving relatively little pain
|
US8957207B2
(en)
|
2009-03-24 |
2015-02-17 |
Proteus S.A. |
Methods for producing phycotoxins
|
CN101940790B
(zh)
*
|
2009-07-01 |
2012-07-25 |
润和生物医药科技(汕头)有限公司 |
一种新型促渗剂组合物及其在透皮给药系统中的应用
|
AU2010279384A1
(en)
|
2009-08-05 |
2012-03-01 |
Wake Forest University |
Compositions and methods for inducing apoptosis in prostate cancer cells
|
US9301962B2
(en)
|
2010-05-14 |
2016-04-05 |
Baylor College Of Medicine |
Male contraceptive compositions and methods of use
|
US20120016308A1
(en)
|
2010-07-16 |
2012-01-19 |
Seventh Sense Biosystems, Inc. |
Low-pressure packaging for fluid devices
|
US20120039809A1
(en)
|
2010-08-13 |
2012-02-16 |
Seventh Sense Biosystems, Inc. |
Systems and techniques for monitoring subjects
|
WO2012064802A1
(en)
|
2010-11-09 |
2012-05-18 |
Seventh Sense Biosystems, Inc. |
Systems and interfaces for blood sampling
|
US20130158468A1
(en)
|
2011-12-19 |
2013-06-20 |
Seventh Sense Biosystems, Inc. |
Delivering and/or receiving material with respect to a subject surface
|
ES2597081T3
(es)
|
2011-04-29 |
2017-01-13 |
Seventh Sense Biosystems, Inc. |
Entrega y/o recepción de fluidos
|
MX2014002115A
(es)
*
|
2011-08-25 |
2014-09-25 |
Nipro Patch Co Ltd |
Parche de piel adhesivo hidratado.
|
DE102011119043A1
(de)
|
2011-11-22 |
2013-05-23 |
Alfred E. Tiefenbacher (Gmbh & Co. Kg) |
Transdermales therapeutisches System (TDS) mit Rotigotin
|
US9301920B2
(en)
|
2012-06-18 |
2016-04-05 |
Therapeuticsmd, Inc. |
Natural combination hormone replacement formulations and therapies
|
HUE055562T2
(hu)
|
2011-11-23 |
2021-11-29 |
Therapeuticsmd Inc |
Természetes kombinációjú hormon helyettesítõ kiszerelések, és terápiák ezekkel
|
JP6342334B2
(ja)
*
|
2012-01-26 |
2018-06-13 |
セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. |
経皮ホルモン補充療法
|
US10806740B2
(en)
|
2012-06-18 |
2020-10-20 |
Therapeuticsmd, Inc. |
Natural combination hormone replacement formulations and therapies
|
US20130338122A1
(en)
*
|
2012-06-18 |
2013-12-19 |
Therapeuticsmd, Inc. |
Transdermal hormone replacement therapies
|
US20150196640A1
(en)
|
2012-06-18 |
2015-07-16 |
Therapeuticsmd, Inc. |
Progesterone formulations having a desirable pk profile
|
US10806697B2
(en)
|
2012-12-21 |
2020-10-20 |
Therapeuticsmd, Inc. |
Vaginal inserted estradiol pharmaceutical compositions and methods
|
US10537581B2
(en)
|
2012-12-21 |
2020-01-21 |
Therapeuticsmd, Inc. |
Vaginal inserted estradiol pharmaceutical compositions and methods
|
US10568891B2
(en)
|
2012-12-21 |
2020-02-25 |
Therapeuticsmd, Inc. |
Vaginal inserted estradiol pharmaceutical compositions and methods
|
US11266661B2
(en)
|
2012-12-21 |
2022-03-08 |
Therapeuticsmd, Inc. |
Vaginal inserted estradiol pharmaceutical compositions and methods
|
US10471072B2
(en)
|
2012-12-21 |
2019-11-12 |
Therapeuticsmd, Inc. |
Vaginal inserted estradiol pharmaceutical compositions and methods
|
US9180091B2
(en)
|
2012-12-21 |
2015-11-10 |
Therapeuticsmd, Inc. |
Soluble estradiol capsule for vaginal insertion
|
US11246875B2
(en)
|
2012-12-21 |
2022-02-15 |
Therapeuticsmd, Inc. |
Vaginal inserted estradiol pharmaceutical compositions and methods
|
WO2014113541A1
(en)
|
2013-01-16 |
2014-07-24 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Attenuated chlamydia vaccine
|
KR20210062693A
(ko)
|
2013-03-15 |
2021-05-31 |
더 칠드런스 메디칼 센터 코포레이션 |
지속성 국소 마취용 네오삭시톡신 조합 제형
|
KR20230145545A
(ko)
|
2013-04-07 |
2023-10-17 |
더 브로드 인스티튜트, 인코퍼레이티드 |
개인맞춤화 신생물 백신을 위한 조성물 및 방법
|
KR20160079123A
(ko)
|
2013-11-22 |
2016-07-05 |
젠자임 코포레이션 |
신경변성 질병을 치료하기 위한 신규한 방법
|
US10801070B2
(en)
|
2013-11-25 |
2020-10-13 |
The Broad Institute, Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer
|
WO2015085147A1
(en)
|
2013-12-05 |
2015-06-11 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
WO2015095811A2
(en)
|
2013-12-20 |
2015-06-25 |
The Board Institute Inc. |
Combination therapy with neoantigen vaccine
|
EP3145489A1
(de)
|
2014-05-22 |
2017-03-29 |
TherapeuticsMD, Inc. |
Natürliche kombinierte hormonersatzformulierungen und therapien
|
AU2015296609A1
(en)
|
2014-07-29 |
2016-12-22 |
Therapeuticsmd, Inc. |
Transdermal cream
|
WO2016100977A1
(en)
|
2014-12-19 |
2016-06-23 |
The Broad Institute Inc. |
Methods for profiling the t-cel- receptor repertoire
|
WO2016100975A1
(en)
|
2014-12-19 |
2016-06-23 |
Massachsetts Institute Ot Technology |
Molecular biomarkers for cancer immunotherapy
|
MX2017014700A
(es)
|
2015-05-20 |
2018-08-15 |
Broad Inst Inc |
Neoantigenos compartidos.
|
US20170000745A1
(en)
*
|
2015-07-02 |
2017-01-05 |
Noven Pharmaceuticals, Inc. |
Transdermal drug delivery systems for levonorgestrel and ethinyl estradiol
|
US10328087B2
(en)
|
2015-07-23 |
2019-06-25 |
Therapeuticsmd, Inc. |
Formulations for solubilizing hormones
|
BR112018070199A2
(pt)
|
2016-04-01 |
2019-01-29 |
Therapeuticsmd Inc |
composição farmacêutica de hormônio esteroide
|
US10286077B2
(en)
|
2016-04-01 |
2019-05-14 |
Therapeuticsmd, Inc. |
Steroid hormone compositions in medium chain oils
|
WO2017184590A1
(en)
|
2016-04-18 |
2017-10-26 |
The Broad Institute Inc. |
Improved hla epitope prediction
|
US11549149B2
(en)
|
2017-01-24 |
2023-01-10 |
The Broad Institute, Inc. |
Compositions and methods for detecting a mutant variant of a polynucleotide
|
WO2020072700A1
(en)
|
2018-10-02 |
2020-04-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
WO2020131586A2
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|